-+ 0.00%
-+ 0.00%
-+ 0.00%

DATROWAY® TYPE II VARIATION APPLICATION VALIDATED IN THE EU AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER WHO ARE NOT CANDIDATES FOR IMMUNOTHERAPY

Reuters·12/18/2025 07:30:00

Please log in to view news